ADMA Biologics
ADMA
ADMA
306 hedge funds and large institutions have $4.16B invested in ADMA Biologics in 2024 Q3 according to their latest regulatory filings, with 93 funds opening new positions, 103 increasing their positions, 95 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11.41% more ownership
Funds ownership: 78.14% → 89.56% (+11%)
8% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 95
Holders
306
Holding in Top 10
7
Calls
$33.2M
Puts
$2.3M
Top Buyers
| 1 | +$305M | |
| 2 | +$76.9M | |
| 3 | +$62.2M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$48.1M |
Top Sellers
| 1 | -$57.1M | |
| 2 | -$36.5M | |
| 3 | -$28.7M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$26.6M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$24.8M |